For COVID-19 updates and guidance, visit For research-related updates, visit

S. David Kimball, Ph.D., Senior Vice President

S. David Kimball, Ph.D., assumed his expanded role as the university's senior vice president for research and economic development in July 2018. His responsibilities include oversight and strategic planning for the university’s more than $700 million in annual research expenditures and management of the many institutional offices and resources that support Rutgers’ research and economic development activities.

Kimball joined the Office of Research and Economic Development in 2011 and has successfully led its translational science and research commercialization efforts. He reorganized and rebuilt the technology transfer capabilities of Rutgers post-merger with the University of Medicine and Dentistry of New Jersey, established a software and copyright licensing group, and built key relationships with external sources leading to the successful funding of Rutgers startups.

Under his leadership as Vice President of Innovation and Research Commercialization, the office achieved record revenues and launched the TechAdvance® gap funding program, which has awarded $1.45 million to 22 Rutgers researchers to help advance their early stage technologies toward commercialization. He continues to advance efforts to standardize and optimize intellectual property, marketing and licensing processes.

Kimball also built the Rutgers University Biomedical Research Innovation Cores (RUBRIC) group, which bridges the gap between basic and interdisciplinary preclinical research for Rutgers faculty, and is a Research Professor in the Ernest Mario School of Pharmacy.

Prior to joining Rutgers, Kimball spent the first 19 years of his career at Bristol-Myers Squibb Pharmaceutical Research Institute, leading drug discovery and development efforts in cardiovascular medicine and oncology. In 2001, he moved to Lexicon Pharmaceuticals in Princeton, NJ as Vice President of Chemistry and directed discovery and development chemistry efforts for Lexicon’s entire small molecule clinical pipeline. Kimball also served as Senior Vice President of Nonclinical Research at Pharmacopeia, Inc., and Chief Scientific Officer of Hydra Biosciences, in Cambridge, MA. He has played a leading role in the discovery and development of a dozen clinical compounds.

Kimball earned his Ph.D. in Organic Chemistry/Chemical Biology from the State University of New York at Stony Brook.